3,073 reports of this reaction
7.3% of all OSIMERTINIB reports
#2 most reported adverse reaction
MALIGNANT NEOPLASM PROGRESSION is the #2 most commonly reported adverse reaction for OSIMERTINIB, manufactured by AstraZeneca Pharmaceuticals LP. There are 3,073 FDA adverse event reports linking OSIMERTINIB to MALIGNANT NEOPLASM PROGRESSION. This represents approximately 7.3% of all 41,863 adverse event reports for this drug.
OSIMERTINIB has an overall safety score of 93 out of 100. Patients taking OSIMERTINIB who experience malignant neoplasm progression should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
MALIGNANT NEOPLASM PROGRESSION is moderately reported among OSIMERTINIB users, representing a notable but not dominant share of adverse events.
In addition to malignant neoplasm progression, the following adverse reactions have been reported for OSIMERTINIB:
The following drugs have also been linked to malignant neoplasm progression in FDA adverse event reports:
MALIGNANT NEOPLASM PROGRESSION has been reported as an adverse event in 3,073 FDA reports for OSIMERTINIB. This does not prove causation, but indicates an association observed in post-market surveillance data.
MALIGNANT NEOPLASM PROGRESSION accounts for approximately 7.3% of all adverse event reports for OSIMERTINIB, making it one of the most commonly reported side effect.
If you experience malignant neoplasm progression while taking OSIMERTINIB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.